151. Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.
- Author
-
Diers AR, Dranka BP, Ricart KC, Oh JY, Johnson MS, Zhou F, Pallero MA, Bodenstine TM, Murphy-Ullrich JE, Welch DR, and Landar A
- Subjects
- Actins physiology, Adaptor Proteins, Signal Transducing physiology, Animals, Cell Line, Tumor, Cell Movement drug effects, Cell Survival drug effects, Cytoskeletal Proteins physiology, Focal Adhesion Kinase 1 physiology, Focal Adhesions drug effects, Kelch-Like ECH-Associated Protein 1, Mice, Neoplasm Metastasis drug therapy, Prostaglandin D2 pharmacology, Signal Transduction, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors, Antineoplastic Agents pharmacology, Prostaglandin D2 analogs & derivatives
- Abstract
Recently, a number of steps in the progression of metastatic disease have been shown to be regulated by redox signalling. Electrophilic lipids affect redox signalling through the post-translational modification of critical cysteine residues in proteins. However, the therapeutic potential as well as the precise mechanisms of action of electrophilic lipids in cancer cells is poorly understood. In the present study, we investigate the effect of the electrophilic prostaglandin 15d-PGJ2 (15-deoxy-Delta12,14-prostaglandin J2) on metastatic properties of breast cancer cells. 15d-PGJ2 was shown to decrease migration, stimulate focal-adhesion disassembly and cause extensive F-actin (filamentous actin) reorganization at low concentrations (0.03-0.3 microM). Importantly, these effects seem to be independent of PPARgamma (peroxisome-proliferator-activated receptor gamma) and modification of actin or Keap1 (Kelch-like ECH-associated protein 1), which are known protein targets of 15d-PGJ2 at higher concentrations. Interestingly, the p38 inhibitor SB203580 was able to prevent both 15d-PGJ2-induced F-actin reorganization and focal-adhesion disassembly. Taken together, the results of the present study suggest that electrophiles such as 15d-PGJ2 are potential anti-metastatic agents which exhibit specificity for migration and adhesion pathways at low concentrations where there are no observed effects on Keap1 or cytotoxicity.
- Published
- 2010
- Full Text
- View/download PDF